Ji X, Chen X, Li K, Zhang Z, Tang L, Li T
Chem Biomed Imaging. 2024; 2(3):168-184.
PMID: 39474146
PMC: 11504603.
DOI: 10.1021/cbmi.3c00093.
Ebner R, Sheikh G, Brendel M, Ricke J, Cyran C
Eur Radiol. 2024; .
PMID: 39387873
DOI: 10.1007/s00330-024-11095-7.
Werner R, Zhi Y, Dreher N, Samnick S, Kosmala A, Higuchi T
Mol Imaging Biol. 2024; 26(5):774-779.
PMID: 39090381
PMC: 11436430.
DOI: 10.1007/s11307-024-01940-y.
Gao J, Zhou J, Liu C, Pan Y, Lin X, Zhang Y
J Cancer Res Clin Oncol. 2024; 150(5):272.
PMID: 38795250
PMC: 11127844.
DOI: 10.1007/s00432-024-05776-5.
Ebner R, Lohse A, Fabritius M, Rubenthaler J, Wangler C, Wangler B
Eur Radiol. 2024; 34(11):7222-7232.
PMID: 38769164
PMC: 11519286.
DOI: 10.1007/s00330-024-10788-3.
Peptide receptor radionuclide therapy (PRRT) in metastatic neuroendocrine tumors of unknown primary (CUP-NETs).
Baum R, Wang P, Jakobsson V, Zhao T, Schuchardt C, Khong P
Theranostics. 2024; 14(1):133-142.
PMID: 38164147
PMC: 10750196.
DOI: 10.7150/thno.88619.
Image-Guided Precision Medicine in the Diagnosis and Treatment of Pheochromocytomas and Paragangliomas.
Gabiache G, Zadro C, Rozenblum L, Vezzosi D, Mouly C, Thoulouzan M
Cancers (Basel). 2023; 15(18).
PMID: 37760633
PMC: 10526298.
DOI: 10.3390/cancers15184666.
Diagnosis, Management and Theragnostic Approach of Gastro-Entero-Pancreatic Neuroendocrine Neoplasms.
Piscopo L, Zampella E, Pellegrino S, Volpe F, Nappi C, Gaudieri V
Cancers (Basel). 2023; 15(13).
PMID: 37444593
PMC: 10340335.
DOI: 10.3390/cancers15133483.
Advances in Radionuclides and Radiolabelled Peptides for Cancer Therapeutics.
Chakraborty K, Mondal J, An J, Park J, Lee Y
Pharmaceutics. 2023; 15(3).
PMID: 36986832
PMC: 10054444.
DOI: 10.3390/pharmaceutics15030971.
PET Criteria by Cancer Type from Imaging Interpretation to Treatment Response Assessment: Beyond FDG PET Score.
Dondi F, Lazzarato A, Gorica J, Guglielmo P, Borgia F, Filice R
Life (Basel). 2023; 13(3).
PMID: 36983767
PMC: 10057339.
DOI: 10.3390/life13030611.
Validation of the SSTR-RADS 1.0 for the structured interpretation of SSTR-PET/CT and treatment planning in neuroendocrine tumor (NET) patients.
Grawe F, Ebner R, Geyer T, Beyer L, Winkelmann M, Sheikh G
Eur Radiol. 2023; 33(5):3416-3424.
PMID: 36964768
PMC: 10121493.
DOI: 10.1007/s00330-023-09518-y.
Integrating Theranostics Into Patient Care Pathways: Expert Panel Narrative Review.
OShea A, Iravani A, Saboury B, Jadvar H, Catalano O, Mahmood U
AJR Am J Roentgenol. 2022; 220(5):619-629.
PMID: 36321986
PMC: 10133840.
DOI: 10.2214/AJR.22.28237.
Quantitative analysis of Ga-DOTA(0)-Tyr(3)-octreotate positron emission tomography/computed tomography imaging for the differential diagnosis of primary pheochromocytoma and paraganglioma.
Ma G, Du J, Zhang X, Liu J, Xu X, Xu B
Quant Imaging Med Surg. 2022; 12(4):2427-2440.
PMID: 35371938
PMC: 8923848.
DOI: 10.21037/qims-21-652.
Training on Reporting and Data System (RADS) for Somatostatin-Receptor Targeted Molecular Imaging Can Reduce the Test Anxiety of Inexperienced Readers.
Weich A, Higuchi T, Bundschuh R, Lapa C, Serfling S, Rowe S
Mol Imaging Biol. 2022; 24(4):631-640.
PMID: 35233654
PMC: 9296379.
DOI: 10.1007/s11307-022-01712-6.
Radiolabeled Somatostatin Analogues for Diagnosis and Treatment of Neuroendocrine Tumors.
Ambrosini V, Zanoni L, Filice A, Lamberti G, Argalia G, Fortunati E
Cancers (Basel). 2022; 14(4).
PMID: 35205805
PMC: 8870358.
DOI: 10.3390/cancers14041055.
Treatment of Neuroendocrine Neoplasms with Radiolabeled Peptides-Where Are We Now.
Naik M, Al-Nahhas A, Khan S
Cancers (Basel). 2022; 14(3).
PMID: 35159027
PMC: 8833798.
DOI: 10.3390/cancers14030761.
Somatostatin Receptor Imaging and Theranostics: Current Practice and Future Prospects.
Park S, Parihar A, Bodei L, Hope T, Mallak N, Millo C
J Nucl Med. 2021; 62(10):1323-1329.
PMID: 34301785
PMC: 9364764.
DOI: 10.2967/jnumed.120.251512.
Narrative review of generative adversarial networks in medical and molecular imaging.
Koshino K, Werner R, Pomper M, Bundschuh R, Toriumi F, Higuchi T
Ann Transl Med. 2021; 9(9):821.
PMID: 34268434
PMC: 8246192.
DOI: 10.21037/atm-20-6325.
Imaging and liquid biopsy in the prediction and evaluation of response to PRRT in neuroendocrine tumors: implications for patient management.
Roll W, Weckesser M, Seifert R, Bodei L, Rahbar K
Eur J Nucl Med Mol Imaging. 2021; 48(12):4016-4027.
PMID: 33903926
PMC: 8484222.
DOI: 10.1007/s00259-021-05359-3.
The Challenge of Evaluating Response to Peptide Receptor Radionuclide Therapy in Gastroenteropancreatic Neuroendocrine Tumors: The Present and the Future.
Liberini V, Huellner M, Grimaldi S, Finessi M, Thuillier P, Muni A
Diagnostics (Basel). 2020; 10(12).
PMID: 33322819
PMC: 7763988.
DOI: 10.3390/diagnostics10121083.